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Regular long term hemodialysis is the accepted method of 
treatment for patients with advanced renal failure. While it is 
effective in maintaining a patient in reasonably good health for long 
periods of time many problems remain, not the least of which is metabolic 
bone disease. This work was undertaken to determine the effects of 
hemodialysis on serum electrolyte and parathyroid hormone levels. It 
was found that the dialysis 'regimen was effective in maintaining 
electrolyte and acid base balance. There was no definite evidence 
to suggest that hemodialysis contributed to the osteodystrophy which 
was evident in some of the patients. 
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INTRODUCTION 
The first practical form of hemodialysis was introduced by 
Scribner et al in 1960. Since then, due to rapid development of 
selectively permiable materials and many improvements in hemodialysis 
equipment and techniques, long term regular hemodialysis has become an 
accepted method of treatment for patients with end stage renal failure (1). 
Thus, many patients who, without hemodialysis would not have survived, are 
able to lead relatively normal and useful lives. 
/ 
Although hemodialysis is effective in removing waste metabolites, 
such as urea, uric acid and creatinine, and in maintaining electrolyte 
balance many problems remain. Of these probably the most distressing 
for the patient are metabolic bone disease and metastatic calcification 
of parenchymous tissue. 
The pathogenesis of the osteodystrophy of renal disease is complex 
and many factors have been implicated. Secondary hyperparathyroidism 
occurs in the early stages of renal failure as evidenced by increased 
serum parathyroid hormone levels ahd parathyroid hyperplasia. This may 
result from a chronic serum ionic calcium deficit (2). Skeletal resistance 
to circulating parathyroid hormone has also been cited as a possible cause 
of renal osteodystrophy (3, 4) and there is much evidence to support each 
2 
theoiry. The increased serum phosphate levels which occur in renal 
failure and are difficult to control by hemodialysis may also play 
a part, either directly or indirectly, in the progress of the disease, 
especially in the metastatic calcification of parenchymous tissue which 
often occurs (5, 6). 
Probably the greatest advance in recent years in our understanding 
of mineral homeostasis was the discovery by De Luca and his co-workers (7, 8) 
and others (9, 10) of the rolfe of the kidney in vitamin D metabolism. 
The object of this study was to determine the effects of hemodialysis 
on plasma electrolytes and parathyroid hormone levels. Special attention 
was given to the levels of ultrafilterable calcium and magnesium, phosphate 
and parathyroid hormone and their possible relationship to renal osteo- 
dystrophy . 
A group of twelve patients on long term hemodialysis was studied 
over a period of five months. In this type of study it is difficult to 
obtain a large series because the number of patients on hemodialysis at any 
given time varies between ten and fifteen. The members of the group are' 
also constantly changing because many of them accept kidney transplant 
and therefore no longer need dialysis. 
The range of ages, length of time on hemodialysis and duration of 
the chronic renal failure prior to commencement of hemodialysis were variables 
which may have influenced the results of the study but were difficult to assess. 
3 
Sample volume and frequency of sampling were also limiting 
factors. As all the patients were anemic it was decided that the 
sample size would be limited to 4 ml of blood, except for two 
occasions when extra samples were taken for parathyroid hormone 
assay. The frequency of sampling was limited to once a month. 
4 
LITERATURE REVIEW 
It is generally accepted that long term regular hemodialysis 
is effective in removing waste products of metabolism from the body and 
in maintaining the electrolyte balance of patients with terminal renal 
failure (1, 13) but it has little or no effect on the osteodystrophy 
which causes so much discomfort and distress and which is often progressive 
/ 
in patients with renal failure (1, 2). 
The biochemical and clinical abnormalities related to the osteo- 
dystrophy of chronic renal failure are similar to those found in pseudo- 
hypoparathyroidism (14). They are, increased circulating parathyroid 
hormone, mild hypocalcemia and iirpaired bone mineralization (15). Thus, 
much of the research carried out on pseudohypoparathyroidism is helpful in 
elucidating the underlying causes of renal osteodystrophy. 
Metabolic acidosis and parathyroid secretion 
The metabolic acidosis which occurs early in chronic renal 
failure has been implicated as a possible cause of secondary hyper- 
parathyroidism, but this was not borne out by the work of Weber et al (16). 
They induced prolonged metabolic acidosis in normal subjects with 
repeated doses of ammonium chloride and found that although calciuria 
5 
occiirred there was no change in intestinal absorption of calcium, 
phosphate or magnesium, and that plasma levels of 25-hydroxychole- 
calciferol and parathyroid hormone did not increase. They concluded 
that neither parathyroid hormone nor vitamin D and its metabolites 
mediate the net bone reabsorption which occurs during acidosis. 
Altered albumin binding of calcium ions 
Alteration of the affinity of albumins for calcium ions has 
/ 
been also suggested as a possible cause of secondary hyperparathyroidism 
in renal failure. Eastman et al (17) have demonstrated that in normal 
subjects the binding of calcium by albumins increases with increase 
in pH. Further experiments by Leme et al (18) have shown that although 
uremic subjects present a mild ionic hypocalcemia at any level of pH, 
their serum albumin-calcium binding is normal. They concluded that 
alterations in the binding affinity of albumins for calcium can be 
excluded as a factor in the hyperparathyroidism of chronic renal failure. 
Magnesium and metabolic bone disease 
Many workers have shown that hypomagnesemia will inhibit para- 
thyroid hormone secretion (19, 20, 21) and that magnesium repletion 
alone will produce a rise in seriim calcium in cases of hypocalcemia 
associated with hypomagnesemia. Targovnich et al (22) demonstrated 
that ionic magnesium is equally as effective as ionic calcium in 
suppressing parathyroid hormone secretion by isolated parathyroid glands 
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in vitro but there is little evidence to suggest that ionic magnesium 
plays any part in the regulation of the parathyroids in vivo. The 
evidence does suggest, however, that ionic magnesium is an activator 
for the enzyme systems responsible for secretion of parathyroid 
hormone. Contiguglia et al (23) found that the total body magnesiiim 
was increased in patients with chronic renal disease and that bone 
was the major reservoir. Their study showed that magnesium replaces 
calcium to a certain degree in the bone matrix of patients with chronic 
renal failure. 
Prostaglandins and bone resorption 
Klein et al (24) have demonstrated that prostaglandins 
stimulate bone resorption in tissue culture and that their effects 
are similar to those of parathyroid hormone. Experiments with para- 
thyroidectomized rats showed, however, that prostaglandin did not 
induce an increase in serum calcium while parathyroid hormone did. 
It is interesting to note that Robertson et al (25) found very high 
levels of prostaglandins in the serum of a patient with renal cell 
carcinoma who exhibited hypercalcemia and a low level of serum para- 
thyroid hormone. They hypothesized that the prostaglandins may have 
either induced the hypercalcemia or were part of a counterregulatory 
event. While prostaglandins may play some part in bone metabolism 
it is probably minor. 
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Skeletal resistance to parathyroid hormone 
Llach et al (2) and Massry et al (2, 9) have shown that 
there is an apparent skeletal resistance to parathyroid hormone in 
patients with chronic renal failure and propose this as a possible 
cause for the secondary hyperparathyroidism which accompanies this 
condition. By inducing hypocalcemia in normal volunteers and in 
patients with chronic renal failure, with ethylene diamine tetra- 
acetate (E.D.T.A.) Llach et al (2) were also able to show that 
patients with renal failure displayed a delayed recovery from acute 
hypocalcemia despite higher than normal parathyroid hormone levels. 
To demonstrate that the apparent skeletal resistance was not 
due to defective parathyroid hormone, Neer et al (12) gave patients 
with pseudohypoparathyroidism, biologically active parathyroid hormone 
from both bovine and human sources. They were unable to detect any 
changes in urinary phosphate or cyclic adenosine monophosphate 
(cyclic AMP) excretion which indicated that there was a lack of end 
organ response in these subjects. More recently Werder et al (24) have 
demonstrated a similar lack of response in another group of patients 
with pseudohypoparathyroidism. 
8 
Impaired parathyroid metabolism 
Martin et al (26, 27) and Hruska et al (28) have demonstrated 
that the kidney is the main site for parathyroid hormone metabolism. 
About 60% of the circulating parathyroid hormone, both intact hormone 
and carboxyl terminal fragments, are removed by the kidney, glomerular 
filtration being the only mechanism for the removal of carboxy]^^ terminal 
fragments. Hepatic uptake on the other hand is selective for the 
f 
intact hormone. Reduced glomerular filtration may therefore account 
for at least some of the increase in plasma parathyroid hormone in 
chronic renal failure. 
The role of calcitonin in renal osteodystrophy 
Many workers have demonstrated that calcitonin plays.an 
inportant role in the prevention of hypercalcemia in animals (29,30,31,32) 
but attempts to demonstrate a similar role in man have been inconclusive. 
A major problem is that several forms of immunoreactive calcitonin 
occur which differ in size and degree of immunoreactivity. Thus 
circulating levels of immunoreactive calcitonin may not reflect 
biological activity (33). Kanis et al (34) found that patients maintained 
on hemodialysis had low levels of circulating immunoreactive calcitonin, 
and that after bilateral nephrectomy their plasma levels of inorganic 
phosphate decreased while their plasma calcitonin levels increased. 
9 
There was also a decrease in osteoblast counts although this was 
transitory. They conclude that low levels of calcitonin may allow 
an increase in bone turnover in chronic renal failure. While this 
is an interesting possibility it is open to question because other 
workers (35) have found higher than normal levels of immunoreactive 
calcitonin in the plasma of patients with chronic renal failure. 
Much of the calcitonin was larger than normal, however, and was^ 
possibly biologically inactive. 
/ 
Because of the uncertainty regarding the biological activity 
of immunoreactive calcitonin it is difficult to correlate plasma levels 
of this hormone with pathological states. 
The role of phosphate in renal osteomalacia 
Recent observations tend to confirm that plasma inorganic 
phosphate levels play an important part in the pathogenesis of renal 
disease. Ibels et al (36), using a remnant kidney model in rats, 
demonstrated that dietary restriction of phosphate prevented renal 
calcification and retarded degeneration of the remnant kidney. They 
concluded that renal calcification was produced by altered phosphate 
metabolism which occurred in the uremic state and that this caused an 
inflammatory and fibrotic reaction which resulted in progressive 
destruction of the kidney. Slatopolsky et al (37) using a remnant 
10 
kidney e^eriment in dogs, dejmonstrated that with a low phosphate 
diet Cless than 100 mg/day) no increase in plasma parathyroid hormone 
occurred, even with a falling glomerular filtration rate. 
Be11avia et al (38) also demonstrated that in rats; 
phosphate, magnesium, or magnesium and phosphate infusion increased 
renal calcium by 50 - 300% and decreased serum phosphate by 20 - 30%. 
They concluded that phosphate infusion may adversely effect parenchymal 
organs, especially the kidneys, when used fp treat hypercalcemia, and 
that magnesium may enhance this effect. Thus, it is important that 
the magnesium and phosphate levels be maintained at near normal levels 
in order to reduce the risk of metastatic calcification of parenchymal 
tissues. 
The role of calcium in osteodystrophy 
While most patients with chronic renal failure have lower than 
normal serum ionic calcium levels, patients on regular hemodialysis 
tend to have ionic calcium levels within normal limits (13 ) . Despite 
this many workers have found that dialysed patients have higher than 
normal serum parathyroid hormone levels (2.). This suggests that a 
factor or factors other than circulating ionic calcium levels play a 
part in the regulation of parathyroid hormone secretion and that this 
factor is missing in patients with renal disease and pseudohypopara- 
thyroidism. 
11 
vitamin D and renal osteodystrophy 
The renal rickets, or osteodystrophy which develops in patients 
with advanced renal failure is histologically similar to the lesions 
produced by chronic vitamin D deficiency. This suggests that defective 
metabolism of vitamin D occurs in renal failure (39, 40). Tanaka et al 
(41) and De Luca (7) have shown that cholecalciferol (vitamin D^) is 
converted to 25-hydroxycholecalciferol by the liver and then furi^er 
hydroxy la ted to 1,25-dihydroxi^ cholecalciferol by the kidney. They, 
and other workers (42,43) have also demonstrated that 1,25-dihydroxy- 
cholecalciferol is the active form of vitamin D which promotes 
absorption of calcium and phosphorus from bone. Drezner et al (44) 
concluded that the hypocalcemia and bone disease in pseudohypoparathyroid- 
ism was probably due to a deficiency of 1,25-dihydroxycholecalciferol. 
Other workers (45,46) have noted that plasma 1,25-dihydroxychole- 
calciferol levels were low or undetectable in patients with renal 
disease even though their plasma 25-hydroxycholecalciferol levels were 
normal. Chesney et al (11) demonstrated that orally administered 
1,25-dihydroxycholecalciferol could reverse the bone disease and increase 
the growth rate of children with renal disease. 
Hausser and McCain (47, 48), in their review of vitamin D 
metabolism,, suggest a model for the regulation of renal 1,25-dihydroxy- 
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cholecalciferol production which implies a negative feedback system 
involving the parathyroid glands. It may be summarized as follows. 
A fall in circulating ionic calcium stimulates the parathyroid 
glands to secrete parathyroid hormone. The parathyroid hormone then 
stimulates the hydroxylation of 25-dihydroxycholecalciferol to 1,25- 
dihydroxy cholecalciferol by the 1-hydroxylase system of the kidney. 
The 1,25-dihydroxycholecalciferol promotes absorption of calcium and 
3 
phosphorus from the intestines and mobilization of calcium and 
phosphorus from bone, thereby increasing the circulating ionic calcium 
which feeds back to the parathyroid glands, shutting off the secretion 
of parathyroid hormone. There is evidence that the parathyroid hormone 
also promotes urinary excretion of phosphate thereby preventing an 
increase in circulating phosphate, which would otherwise result from the 
action of 1,25-dihydroxycholecalciferol (49, 50). There is also evidence 
to suggest that 1,25-dihydroxycholecalciferol has an inhibiting effect on 
parathyroid secretion (47, 48). 
It is probable that failure of the renal 1-hydroxylase system of 
the kidney in the early stages of chronic disease, is responsible for the 
hyperparathyroidism and osteodystrophy of chronic renal failure (11). 
The role of other vitamin D metabolites such as 24,25-dihydroxy- 
cholecalciferol is yet to be determined but it is possible that they may 
also play a part in mineral homeostasis. 
/ 
- 13 - 
MATERIALS AND METHODS 
Patients A group of twelve patients on regular hemodialysis 
were studied at monthly intervals over a period of five months. 
The hemodialysers used were Travenol RSP (recirculating single 
pass) instruments (Travenol Ltd., 6400 Northam Drive, Malton, Ontario) 
equipped with Gambro Lundia parallel flow dialysers (Gambro (Canada) 
Ltd., 2000 Argentia Rd., Mississauga, Ontario). The dialyser bath 
solution was obtained as a liquid concentrate from Travenol and was 
diluted with deionized water to a final volume of 12 liters just 
before use. The final composition of the bath fluid in m. mol. 1~^ 
was sodium 134, potassium 1.0, calcium 1.5, magnesium 0.75 and 
acetate 37. 
The patients are listed by number in table 1. Three of the 
group were originally diagnosed as chronic pyelonephritis and the 
remainder as glomerulonephritis. Patients 1, 4, 7 and 11 had radio- 
logical and clinical evidence of osteomalacia. A partial parathyroid- 
ectomy was performed on patient number 4 three months prior to the 
commencement of this study. 
Blood Samples Blood samples from patients on hemodialysis 
were obtained from their arterio-venous shunts just prior to and at 
14 
the completion of dialysis. The samples were placed in plain (red 
stoppered) Vacutainer tubes and allowed to clot at room temperature. 
After centrifugation at 2 500 rpm for approximately 15 minutes, the 
sera were removed and placed in capped plastic vials No. 566353 
Beckman Instruments, Fullerton, California, U.S.A. Samples for 
parathyroid hormone analysis were stored at -20^C. Because most 
of the patients were anemic the sample size was limited to 4 ml of 
whole blood or less. 
Serum sodium and potassium Serum sodium and potassium levels 
were determined by flame photometry using the I.L. 343 flame photometer 
equipped with an in-line dilutor (Instrumentation Laboratory, 
Lexington, Mas. U.S.A.) 
Serum chloride and total carbon dioxide Serum chloride and 
total carbon dioxide were measured with a semiautomated analyser 
I.L. 446 which employs a mercuric thiocyanate method for chloride 
and a PCO^ electrode system for total carbon dioxide measurements. 
(Instrumentation Laboratory, Lexington, Mas., U.S.A.) 
Serum inorganic phosphate Serum inorganic phosphate was 
measured by the method of Goldberg et al (51 ) based on the classic 
phosphotungstate method with ferrous ions as the reducing agent. 
15 
Blood pH Blood pH levels were determined at 37^C with a 
Radiometer ABL-1 blood gas analyser (Bach-Simpson Ltd., London, 
Ontario) 
Serum pH Serum pH was measured with a Beckman model 3500 
digital pH meter. (Beckman Instruments, Fullerton, California, U.S.A.) 
Serum ultrafiltrate^ Serum ultrafiltrates were prepared with 
Centriflo membrane cones No. CF50A with a retention cut off at 50 000 MW, 
obtained from Amicon Corporation, Lexington, Mass., U.S.A. The 
membranes were soaked in distilled water for a minimum of two hours 
prior to use. They were then centrifuged for 15 minutes at 2 000 rpm 
to remove excess water in order to eliminate dilution of the serum 
ultrafiltrates. Results of preliminary experiments made with the 
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Total and ultrafilterable serirni calcium and magnesi-um 
Total and ultrafilterable serum calcium and magnesium measurements 
were made with a Jarrell Ash/Fisher model 850 computer controlled 
atomic absorption spectrophotometer (Fisher Scientific Company, 
Toronto, Ont.) with lanthanum chloride as dilutent. Dilutions of 
sera were made with a Cordis automatic dilutor (Cordis Corporation, 
Miami, Fla., U.S.A.). 
Serum parathyroid hormone Serum parathyroid levels were 
measured by a double antibody radioimmunoassay method using reagents 
supplied by the Cambridge Nuclear Corporation, Billerica, Mass., U.S.A. 
Statistical methods Both linear regression analysis and the 
Student's t test were used to analyse the experimental data. 
The "Student's" t test values were calculated from the mean 
and standard deviation values for the various measures by the 
following method. 





/ 1/N^ + l/N^ 
where X is the mean, S is the standard deviation and N is the 
population size. 
Probability values were calculated from the Student's t 
values as two tailed probabilities. A probability (p) of less 
than 0-01 was taken to indicate that there was a significant 
difference between the two parameters- 
19 
P RE L I M l N A R Y S T U D I E S 
The effects of centrifugation and temperature change on ultra- 
filterable calciiim. 
It has been reported by other workers ( 52 ) that protein binding 
of calcium increases with increase in pH. The following experiments 
were therefore used to determine the extent of pH change occurring 
during the preparation of samples for ultrafilterable calcium 
/ 
measurements. 
Twenty 10 ml blood samples were obtained from healthy adult 
donors ranging in age from 20 to 45 years. Each sample was drawn into 
a plain (red stoppered) Vacutainer tube and allowed to clot at room 
temperature for approximately 45 minutes. The pH of the supeimatant 
serum was measured at 37°C using the Radiometer ABL-1 blood gas 
analyser. After centrifugation of the stoppered tubes at 2 500 rpm 
for 15 minutes the pH of the serum was again measured at 37°C and also 
at room temperature (23 C). The results are recorded in table 2. 
There was no significant difference between the two measure- 
o 
ments at 37 C (p = 1.0) which indicated that there was no loss of 
carbon dioxide during centrifugation. The range of differences between 
, o o 
the 37 C and 23 C pH measurements was 0.2 + 0.02 or 0.014 + 0.002 pH 
units per C° decrease in temperature. This value corresponded to'the 
values obtained by other workers (53). 
20 - 
TABLE 2 
EFFECTS OF CENTRIFUGATION AND TEMPERATURE CHANGE ON 
BLOOD SAMPLES FROM NORMAL ADULTS 
Sairple 
No. 
Initial pH after centrifugation 



















































































































EFFECTS OF CENTRIFUGATION AND TEMPERATURE CHANGE ON BLOOD 




pH at 37^ 
pH after centrifugation 










































































A Study was also carried out on blood samples from the patient 
group (see table 3). The results were similar to those of the normal 
o o 
group (p = 0.20) . The range of pH change between 37 C and 23 C was 
0.19 + 0.02. 
Based on these findings and the work of Halver ^ (54) a 
correction factor for ultrafilterable calcium measured at room 
temperature was devised. 
Correction factor 
Measured UF Ca (m mol 1 ^) + 0.4(0.014)(37.0 - t) 
Measured UF Ca (m mol 1 ^) + 0.0056(37.0 - t) 
where 0.4 = UF Ca (m mol 1 ^)/pH unit increase (72) 
0.014=ApH/C° (72) 
, . ■ o t = working temperature in C 
Because of limited sample size it was impractical to measiire 
the pH of each patient sample so the above factor was used to correct 
o 
serum ultrafilterable calcium levels to the value at 37 C. 
Assessment of Centriflo membrane cones 
The Centriflo membrane cones, used to obtain ultrafiltrates by 
centrifugation, required preliminary soaking in distilled water and in 
order to avoid dilution of the ultrafiltrate it was necessary to make 
23 
sure tJiat residual water was removed before introduction of the 
serum. To do this the membranes were removed from the water and 
placed in conical supports, they were then centrifuged at 2 000 rpm 
for varying lengths of time. A pooled serum sarrple was then used 
to measure the degree of dilution produced by the residual water. 
1 ml aliquots of the serum pool were added to the membranes and 
they were placed in dry centrifuge tvibes and centrifuged for 20 minutes 
at 2 000 rpm. Each ultrafiltrate was then analysed for calcium by 
/ 
atomic absorption. It was found that preliminary centrifugation for 
15 minutes at 2 000 rpm was adequate for removal of residual water. 
Effects of hemodialysis on serum electrolytes 
The effects of hemodialysis on serum electrolytes were investi- 
gated by measuring their concentrations just prior to and immediately 
after hemodialysis. 
Sodium The pre aj^id post dialysis serum sodium levels were 
138 + 2.4 m mol 1 and 137 + 2.2 m mol 1 ^ respectively. Except 
for three of the pre and four of the post dialysis levels the results 
-1 were within the generally accepted range of 134 - 145 m mol 1 ( 55 ) 
for normal adults. Comparison of the pre with the post dialysis ranges 
did not reveal any significant difference (p = 0.03). The data for 
serum sodium is given in table 4. 
Potassium The average decrease in serum potassium during 
dialysis was 1.4 + 0.5 m mol 1 The pre dialysis serum potassium 
levels were 4.8 + 0.7 m mol 1 ^ and the post dialysis 3.3 + 0.5 m mol 1 
Before dialysis the range of serum potassium levels was significantly 
high (p = -<0.001) and after dialysis significantly lower (p = -^0.001) 
than the range for normal adults of 3.5 - 5.0 m mol 1 ^ (55). 






















































































All values are in 
Pre dialysis X = 138, S = 2.4 m mol 1 
Post dialysis X = 137, S = 2.2 
Pre vs Post dialysis values 
t = 2.36 
p = 0.025 
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TABLE 5 


































































All above values are in m mol 1 
Pre vs Post dialysis - t = 15, p = 0.001 






























COMPARISON OF PRE AND POST DIALYSIS SERUM TCO , Cl AND PO 
2 4 






































































94 1,28 1.17 







Pt# T CO, Cl PO 





18.0 25.1 101 
8 20.0 25.7 96 
18.5 21.8 98 
9 20.4 23.4 96 
20.4 25.3 96 




19.0 20.3 101 
11 20.8 25.6 102 
98 
12 19.0 24.8 98 


















T CO, Cl PO 
X X 
Pre 20.7 2.8 
Post 25.0 2.4 
t = 6.25 Pre 
vs 
Post p <0.001 
98.2 
96.6 
t = 1.9 


























Chloride A conparison of pre and post dialysis serirn 
chloride levels is given in table 6 . There was no significant 
change in serum chloride levels during dialysis (p = 0.067). The 
pre and post levels were 98.2 + 3.3 m mol 1 ^ and 96.1 + 3.1 m mol 1 ^ 
respectively. 
Total serum carbon dioxide Total serum carbon dioxide 
(T CO^) levels increased significantly during dialysis (p = ^0.001). 
T CO^ levels were 20.7 + 28 m mol 1 ^ before^, and 25 + 2.5 m mol 1 ^ 
after dialysis. The average increase during dialysis was 4.3 + 0.9 m 
mol 1 Data for serum T CO^ is given in table 6. 
Inorganic phosphate A decrease of 0.89 + 0.38 m mol 1 ^ in 
inorganic phosphate occurred during dialysis. The pre and post dialysis 
-1 -1 
levels were 2.21 j- 0.54 m mol 1 and 1.30 + 0.31 m mol 1 respectively. 
Data for serum inorganic phosphate is given in table 6. 
Total serum calcium Because variations in serum calcium occur 
with change in position ( 56 ) the patient results were compared with a 
noirmal ambulatory control group (Table 7 ) and with a group of supine 
hospital patients (Table 9 ) none of whom had evidence of renal, para- 
thyroid or bone disease. The pre dialysis total serum calciiam range of 
2.27 + 0.22 m mol 1 ^ did not differ significantly from the range of 
the supine control group (p = 0.55) but was significantly below the 
29 
TABLE 7 
SERUM CALCIUM AND MAGNESIUM LEVELS IN 20 NORMAL SUBJECTS 
































































X 2.40 1.28 0.530 0.78 0.57 0.680 
S 0.08 0.08 0.020 0.02 0.02 0.020 
T Ca = total calcium, UF Ca = ultrafilterable calcium 
Values are in m mol 1 ^ 




SERUM CALCIUM AND MAGNESIUM LEVELS IN 25 HOSPITAL 








































































































































































levels of the normal ambulatory group (p = <10.001). Post dialysis 
values of 2.42 m mol 1 ^ on the other hand were significantly higher 
than those of the supine control group (p = < 0.001) but within 
the range of the normal ambulatory group (p = 0.52). Data for serum 
total calcium is given in tables 9 and 15. 
Ultrafilterable serum calcium The pre dialysis ultra*- 
filterable serum calcium (yF Ca) levels of 1.19 + 0.15 m mol 1 ^ 
were significantly higher than those of the supine controls (p =*<-0.001). 
but were lower than the normal ambulatory controls (p = < 0.001). The 
UF Ca levels increased during dialysis so that the post dialysis 
levels of 1.28 + 0.17 m mol 1 ^ were higher than those of the 
supine control group (p = <10.001) but within the range of the 
normal ambulatory group (p = 1.00). Data for UF Ca is given in 
tables 10 and 15. 
Ultrafilterable/total serum calcium ratios The ultra- 
filterable/total serum calcium ratios (UF/T Ca) for the pre dialysis, 
post dialysis and normal ambulatory group were similar (p = 0.50, 
0.55, and 0.88 respectively), while the ratios for the supine group 
were significantly lower (p = ^ 0.001). UF/T Ca ratios for the pre 
and post dialysis samples were 0.52 + 0.07 and 0.53 + 0.08 respectively. 
Data for UF/T Ca ratios is given in tables 11 and 15. 
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TABI£ 9 
PRE 7\ND POST DIALYSIS TOTAL SERUM CALCIUM 






































































Pre dialysis calcium X =2.27 S= 0.22 
Post dialysis calcium X = 2.42 S= 0.21 
















































































1.18 1.48 1.34 1.30 
Pre Post Pre 
1.29 1.05 0.98 
1.23 1.08 1.23 
1.13 1.28 1.13 
1.15 1.48 1.03 
1.53 1.48 1.15 
1.23 1.28 1.28 
1.28 1.28 1.15 
1.19 1.39 1.03 
1.08 1.43 1.00 
1.18 1.16 1.53 
0.87 1.23 1.28 
1.14 
All above values are in m mol 1 -1 
Pre dialysis UFCa X=1.19 S=0.15 
Post dialysis UFCa X=1.28 S= 

















PRE AND POST DIALYSIS ULTRA?ILTERABLE/TOTAL CALCIUM 



































































Pre dialysis UF/T Ca X = 0.52 S = 0.07 
Post dialysis UF/T Ca X=0.53 S= 
















Total serum magnesiiim The data for serum magnesium is given 
in table 13. The pre and post dialysis levels of 1.2 7 + 0.18 m mol 1 ^ 
and 1.19 m mol 1 ^ were significantly higher than either of the control 
groups (p = -<.0.001) . Comparison of the pre and post dialysis ranges 
revealed that there was a significant decrease in total serum magnesium 
during dialysis (p = 0.009). 
The ambulatory controls had significantly lower total serum 
/ 
magnesium levels than the supine controls (p^ = -<0.001). 
Ultrafilterable serum magnesium The pre and post ultra- 
filterable serum magnesium (UF Mg) levels of 1.00 + 0.02 m mol 1 ^ 
and 0.91 + 0.02 m mol 1 ^ were significantly higher than either the 
ambulatory (p = <-0.001) or supine (p = <0.001) groups. The pre 
dialysis levels were also significantly higher than the post dialysis 
levels (p = 0.001) indicating that there was a significant decrease 
in UF Mg during dialysis. Data for UF Mg is given in table 13 and 15. 
Ultrafilterable/total serum magnesium ratio The pre dialysis 
ultrafilterable/total serum magnesium ratio (UF/T Mg) range of 0.77 + 0.08 
was not significantly different from the post dialysis range of 0.77 + 
0.09 (p = 0.20) and both ranges were significantly higher than either 
the ambulatory control or supine control groups. The supine UF/T Mg 
ratios of 0.61 + 0.07 were significantly lower than those of the 
ambulatory control groups (0.68+0.02) (p = < 0.001). Results are 
given in tables 14 and 15. 
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TABLE 12 
PEE AND POST DIALYSIS TOTAL SERUM MAGNESIUM 




































































values are in m mol 1 
Pre dialysis total magnesium -X=1.27 S=0.18 
Post dialysis total magnesium - X = 1.19 S = 





















































































All above values are in m mol 1 
-1 
Pre dialysis UF Mg X = 1.00 S = 0.02 
Post dialysis UF Mg X = 0.91 S = 

















PRE AND POST DIALYSIS ULTBAFILTERABLE/TOTAL MAGNESIUM 
Mont±i 





























































All above values are in m mol 1 
Pre dialysis UF/T Mg X = 0.97 S = 0.08 
Post dialysis UF/T Mg X = 0.77 S = 0.09 















TAB IE 15 






































Pre vs Post -3.96 
Pre vs Normal -4.95 
Post vs Normal 0.67 
Pre vs In Pat. 0.60 


















<0.001 Normal vs In.Pt. 8.47 















Pre vs Post 
Pre vs Normal 
Post vs Normal 
Pre vs In Pat. 


































Post vs In Pat. 16.20 
Normal vs In Pat.3.15 
X = mean, S - 











Blood pH Blood pH measurements, taken just prior to and 
immediately after hemodialysis indicated that there was a small but 
significant increase in blood pH during dialysis (p = 0.006). The 
pre dialysis range was 7.382 + 0.056 and the post dialysis 7.436 + 
0.037. The data for blood pH is given in table 16. 
Effects of hemodialysis on parathyroid hormone 
Serum immunoreactive parathyroid hormone (iPTH) levels were 
measured on samples obtained from the patients at the beginning of 
the study and again after a three month interval. The results are 
given in table 17. 
Although patient number 7 showed a decrease, and patient 
number 10 an increase in iPTH during dialysis, there was no significant 
difference between the pre and post dialysis iPTH levels (p =0.61). 
The three patients, numbers 1, 7 and 11, with clinical and 
radiological evidence of osteodystrophy, had significantly higher serum 
iPTH levels than the other members of the group. The pre dialysis 
range for patients with osteodystrophy was 16 219 + 5 544 pg ml ^ while 
the range for the other members of the group was 3 871 + 2 882 pg ml 
41 
TABLE ■ 16 




































X 7.382 X 7. 
s 0.056 s 0. 
Pre vs Post dialysis pH t = -3.11 















































COMPARISON OF PRE AND POST DIALYSIS 
SERUM PARATHYROID HORMONE LEVELS 
Time on Initial iPTH after Evidence of bone 
dialysis iPTH** 3 months** disease 









































































* After removal 
** Values are in 






Figure 1. Comparison of ultrafilterable calcium with parathyroid 
hormone 
Although patient number 4 had osteomalacia she was not included in this 
group because her parathyroid glands were removed three months prior to 
the commencement of this study. 
Comparison of pre dialysis electrolytes with parathyroid hormone 
levels 
In order to determine whether there was any correlation between 
the pre dialysis electrolyte and serum parathyroid hormone levels, the 
results were coirpared by linear regression analysis. 
The pre dialysis ultrafilterable calcium levels did not correlate 
with the serum parathyroid hormone levels as shown in Figure 1. Ultra- 
44 
Figure 2. Coirparison of ultrafilterable/total calcium 
ratios with parathyroid hormone levels. 
filterable/total calcium ratios on the other hand were found to be related 
by the equation y = 141.7x+ 81 with a correlation coefficient r = —0.87 
(see Figure 2). 
Inorganic phosphate (Figure 3), ultrafilterable magnesium (figure 4) 
and ultrafilterable/total magnesium ratios (Figure,. 5) did not correlate 
with the serum parathyroid hoirmone levels as indicated by their correlation 













Figure 3 Comparison of sertfm inorganic phosphate 
with parathyroid hormone levels 
Figure 4 Comparison of serum ultrafilterable magnesium with 













UF/T magnesium ratio 
Figure 5 Comparison of ultrafilterable/total magnesium 
ratios with parathyroid hormone levels. 
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CONCLUSIONS 
The results of this study indicate that the serum sodium and 
chloride levels of the patients were well controlled by the hemo- 
dialysis regimen, in that there was no significant difference between 
the pre and post dialysis values for these ions. Other inorganic ions 
showed varying degrees of change between dialyses but were adequately 
controlled. 
There was an increase in serum inorganic phosphate between 
dialyses and the pre dialysis levels were generally above the normal 
adult range of 0.8 - 1.53 m mol 1 (55) even though the patients 
were given oral alviminum hydroxide in order to limit their intestinal 
uptake of phosphate. During dialysis the serum inorganic phosphate 
decreased by 0.89 + 0.38 m mol 1 ^ and post dialysis levels of serum 
inorganic phosphate were generally within the normal range. During 
this study none of the patients had post dialysis levels below the 
normal range, thus hypophosphatemia was not a cause of bone deminerali- 
zation in these patients. Pre dialysis hyperphosphatemia on the other 
hand may increase the risk of metastatic calcification of parenchymous 
tissue. 
Although serum potassium levels increased between dialyses. 
they remained within reasonable limits with only 5% of the values 
48 
a±)Ove the adult normal range of 3.6 - 5.5 m mol 1^ (55). The 
mean decrease in potassium during dialysis was 1.43 + 0.49 m mol 1 
67% of the post dialysis potassium values were below the lower limit 
of the normal range but were above the level which could cause 
cardiac arhythmia. 
The pre dialysis total serum carbon dioxide levels were close 
to the lower limits of the normal adult range of 22 - 29 m mol 1 ^ (55) 
but rose to within the normal'range during dialysis. The mean increase 
during dialysis was 4.3 + 0.9 m mol 1 Both the pre and post dialysis 
pH values were generally within the normal range for adults, 7.35 - 7.42 (55), 
therefore systemic acidosis was not a cause of bone demineralization in 
these patients. 
Serum calcium results were more difficult to assess in as much as the 
supine position (which these patients maintained during the five hours of 
dialysis) tends to lower serum calcium levels. The pre dialysis total serum 
calciiim and ultrafilterable calcium levels were lower than the post dialysis 
levels, and those of the ambulatory control group. The pre dialysis ultra- 
filterable/total calcium ratios were similar to the post dialysis UF/T Ca ratios 
(p = 0.5) and those of the ambulatory control group (p = 0.55). Although the 
total calcium levels of the supine control group were similar to the pre 
dialysis levels, the ultrafilterable calcium and UF/T Ca ratios were 
significantly lower than the pre dialysis levels of the patient group 
(p = 0.001). While the pre dialysis ultrafilterable calcium levels were 
49 
slightly lower than those of the normal ambulatory controls their 
significance is questionable because blood samples were obtained 
from the patients in the supine position. 
Total and ultrafilterable magnesium levels were elevated in 
both the pre and post dialysis samples and were approximately 1.5 
times higher than those of the normal ambulatory group. The ultra- 
filterable/ total magnesium ratios of the pre dialysis samples were 
/ 
also significantly higher than those of the normal controls. There 
was a decrease in both total and ultrafilterable magnesium during 
dialysis but the ultrafilterable/total magnesium ratios did not change 
significantly (p = 0.2). As all the patients had increased serum para- 
thyroid hormone levels it follows that ionic magnesium in higher than 
normal concentrations does not suppress parathyroid hormone secretion 
in vivo as was suggested by the work of Targovnich et al (22) who found 
that ionic magnesium was as effective as ionic calcium in suppressing 
parathyroid hormone secretion in isolated parathyroid glands. 
Serum parathyroid hormone levels appear to be a significant 
indicator of bone disease in that the patients with clinical and radio- 
logical evidence of osteodystrophy had serum parathyroid hormone levels 
in excess of 10 000 pg ml while patients without evidence of osteo- 
dystrophy had parathyroid hormone levels significantly lower than this. 
50 
Although comparison of the ultrafilterable/total calcium ratios 
with parathyroid hormone levels by linear regression analysis indicated 
an inverse relationship between them, the number of observations were 
too small for any definite conclusions to be made. 
Comparison of serum parathyroid hormone levels with inorganic 
phosphate (Figure 5), ultrafilterable calcium (Figure 1), ultrafilterable/ 
/ / 
total calcium ratios (Figure 2) , ultrafilterable magnesiiom (Figure 4) and 
ultrafilterable/total magnesium ratios (Figure 5) by linear regression 
analyses did not reveal any significant relationships. 
The results of this study have shown that the regimen of five hours 
dialysis every three days is adequate to maintain electrolyte and acid/base 
balance and that there is no evidence to suggest that fluctuations in 
electrolyte levels between dialyses play any part in the pathogenesis 
of osteodystrophy. 
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